The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwMDS 2025 | Advances made in MDS classification and risk stratification: ongoing work & future perspectives
In this discussion, Uma Borate, MD, The Ohio State University, Columbus, OH, Luca Lanino, MD, PhD, Yale University, New Haven, CT, Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, and Zoey Xie, MD, MS, Moffitt Cancer Center, Tampa, FL, discuss updates in the classification and risk stratification of myelodysplastic syndromes (MDS). They first discuss changes that have been made in disease prognostication, highlighting the increasing importance of genetic features in defining disease groups. The experts also comment on the potential of using artificial intelligence (AI) to aid clinicians, and conclude by sharing insights into the precursor conditions clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). This discussion took place at the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
